PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.37
Below 0.5x CRVO's 7.13. Michael Burry might see potential near-term liquidity strain.
1.37
Below 0.5x CRVO's 7.13. Michael Burry might foresee solvency or liquidity crises in a downturn.
1.32
Below 0.5x CRVO's 6.57. Michael Burry could foresee potential liquidity shocks if times get tough.
No Data
No Data available this quarter, please select a different quarter.
-46.77
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.